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Pancreatic ductal adenocarcinoma (PDA) has a prominent
stroma which includes collagen, lymphoid, myeloid, and
stellate cells. Adequate preclinical models are needed to
advance immunotherapy for PDA. Indeed many xenograft
models poorly mimic the morphology, stroma, and pheno-
type of the human PDA microenvironment. Thus, further
development and use of relevant spontaneously arising
genetically engineered murine models (GEMM) of PDA is
important for accurate preclinical assessment of immune
therapies. We have demonstrated that PDA-associated stel-
late cells promote the differentiation of myeloid-derived
suppressor cells (MDSC) in a STAT3-dependent manner.
Thus it is important that tumor and stroma in murine
PDA models recapitulate a human patient’s immune phe-
notype. To date, the contribution of various cytokines or
soluble factors in these models has not been well charac-
terized. We hypothesized that various pancreatic cancer
GEMM would accurately replicate alterations in STAT3
signaling and immune suppressive phenotypic properties
both systemically and within the tumor microenvironment.
We examined the role of IL-6/STAT3 signaling within the
microenvironment from four separate spontaneously aris-
ing GEMM of PDA (KPC, BRCA1-KPC, BRCA2-KPC, and
Mist1(KRasG12D/+) which recapitulate human tumors.
KPC, BRCA-KPC, and Mist1(KRasG12D/+) mice develop
spontaneously arising KRAS mutant (TP53 and BRCA2
mutant, respectively) pancreatic tumors. Similar to human
PDA, fibrosis was evident in all tumors, with cystic regions
found in BRCA1-KPC tumors. Murine pancreatic stellate
cells from Mist1(KRasG12D/+) were alpha-SMA+ and pro-
duced IL-6 similar to human stellate cells. STAT3 was con-
stitutively phosphorylated at Tyr705 in both malignant
and stromal cells of the tumor microenvironment in
each GEMM. Similar to patients with advanced PDA,
high-throughput bioplex analysis revealed plasma from
tumor-bearing mice contained high levels of IL-6 (mean
4729 pg/ml) and other important inflammatory factors.
Time course data from the Mist1(KRasG12D/+) GEMM
revealed elevated levels of MDSC at early stages of
3 months (4.6%±1.7), with higher levels (8.9%± 0.3) by
8 months as compared to healthy, age matched littermates
(2.3%). Similarly, MDSC were significantly higher in
BRCA1-KPC mice (14.2%±5.4; mean age 77 days) versus
healthy, age-matched littermates (3.94%±0.3; mean age 67
days). These data demonstrate that multiple spontaneously
arising GEMM for PDA display a phenotype comparable
to the microenvironment of human patients. Future studies
will take advantage of these properties and use these mod-
els for therapeutic evaluation of agents targeting the IL-6/
JAK/STAT pathway within the tumor microenvironment.
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